首页 > 最新文献

European Cardiology Review最新文献

英文 中文
HDL Mimetics Enhances Mitochondrial Function via Stimulation of PGC1-α. HDL模拟物通过刺激PGC1-α增强线粒体功能。
IF 3 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO10
Hang Zhang, Tomohiro Komatsu, Shihoko Nakashima, Satomi Abe, Emi Kawachi, Satoshi Imaizumi, Keijiro Saku, Yoshinari Uehara
{"title":"HDL Mimetics Enhances Mitochondrial Function via Stimulation of PGC1-α.","authors":"Hang Zhang, Tomohiro Komatsu, Shihoko Nakashima, Satomi Abe, Emi Kawachi, Satoshi Imaizumi, Keijiro Saku, Yoshinari Uehara","doi":"10.15420/ecr.2023.18.PO10","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO10","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/c4/ecr-18-e27.PMC10316335.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9858333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Presentation Award Winner: LDL-C Reduction in Diabetic Patients after Percutaneous Coronary Intervention: Is There any Difference with Non-diabetic? 口头报告奖得主:经皮冠状动脉介入治疗后糖尿病患者LDL-C降低:与非糖尿病患者有区别吗?
IF 3 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO2
N Mallofré, G Torres, C Roca, P Rojas, M Sutil, N Casanovas, M Lloreda, F Castaldo, E Bosch, A Martínez-Rubio
{"title":"Oral Presentation Award Winner: LDL-C Reduction in Diabetic Patients after Percutaneous Coronary Intervention: Is There any Difference with Non-diabetic?","authors":"N Mallofré, G Torres, C Roca, P Rojas, M Sutil, N Casanovas, M Lloreda, F Castaldo, E Bosch, A Martínez-Rubio","doi":"10.15420/ecr.2023.18.PO2","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO2","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/2f/ecr-18-e19.PMC10316379.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9793291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Present and Future Perspectives on the Role of Biomarkers in Atherosclerotic Cardiovascular Disease Risk Stratification. 生物标志物在动脉粥样硬化性心血管疾病风险分层中的作用的现状和未来展望
IF 3 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.15420/ecr.2022.57
Bruna Gigante
© The Author(s) 2023. Published by Radcliffe Group Ltd. www.ECRjournal.com Atherosclerotic cardiovascular diseases (ASCVD) remain the leading cause of death in Europe, with more than 4 million deaths in 2017.1 Ischaemic heart disease and stroke account for 82% of disability-adjusted life years (DALYs) in European Society of Cardiology member countries, even though ASCVD incidence has declined during the past 27 years.1
{"title":"Present and Future Perspectives on the Role of Biomarkers in Atherosclerotic Cardiovascular Disease Risk Stratification.","authors":"Bruna Gigante","doi":"10.15420/ecr.2022.57","DOIUrl":"https://doi.org/10.15420/ecr.2022.57","url":null,"abstract":"© The Author(s) 2023. Published by Radcliffe Group Ltd. www.ECRjournal.com Atherosclerotic cardiovascular diseases (ASCVD) remain the leading cause of death in Europe, with more than 4 million deaths in 2017.1 Ischaemic heart disease and stroke account for 82% of disability-adjusted life years (DALYs) in European Society of Cardiology member countries, even though ASCVD incidence has declined during the past 27 years.1","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/d3/ecr-18-e13.PMC10316363.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9793293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Heart Failure-Exacerbating Medications among Heart Failure Patients in a Tertiary Referral Centre in Malaysia. 在马来西亚三级转诊中心心力衰竭患者中使用心力衰竭加重药物。
IF 3 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO20
Yii Ching Wong
{"title":"Use of Heart Failure-Exacerbating Medications among Heart Failure Patients in a Tertiary Referral Centre in Malaysia.","authors":"Yii Ching Wong","doi":"10.15420/ecr.2023.18.PO20","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO20","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/50/e1/ecr-18-e37.PMC10316340.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study. Evolocumab在中欧和东欧的LDL-C水平比指南中推荐的高得多的患者中开始使用:观察性HEYMANS研究的结果。
IF 3 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO19
V Blaha, R Margoczy, I Petrov, A Postadzhiyan, K Raslova, H Rosolova, I Bridges, N N Dhalwani, M Zachlederova, K K Ray
{"title":"Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study.","authors":"V Blaha, R Margoczy, I Petrov, A Postadzhiyan, K Raslova, H Rosolova, I Bridges, N N Dhalwani, M Zachlederova, K K Ray","doi":"10.15420/ecr.2023.18.PO19","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO19","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/cb/ecr-18-e36.PMC10316339.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Difficulties in Monitoring Antithrombotic Therapy in Patients with Atrial Fibrillation and Post-traumatic Hepatic and Splenic Visceral Haematomas. 心房颤动和创伤后肝、脾脏器血肿患者抗血栓治疗监测的困难。
IF 3 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO14
Maria Cristina Beznă, Suzana Dănoiu, Marinela Beznă, Iulia-Andreea Voișneanu, Amelia Genunche-Dumitrescu, Larisa Săndulescu
{"title":"Difficulties in Monitoring Antithrombotic Therapy in Patients with Atrial Fibrillation and Post-traumatic Hepatic and Splenic Visceral Haematomas.","authors":"Maria Cristina Beznă, Suzana Dănoiu, Marinela Beznă, Iulia-Andreea Voișneanu, Amelia Genunche-Dumitrescu, Larisa Săndulescu","doi":"10.15420/ecr.2023.18.PO14","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO14","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/69/ecr-18-e31.PMC10316343.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Approach to Anticoagulation Therapy in Patients with Combined Atrial Fibrillation and Coronary Artery Stents: A Review of the Literature. 房颤合并冠状动脉支架患者的抗凝治疗方法:文献综述。
IF 3 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO4
Ben Borokhovsky, Perry J Weinstock
{"title":"Approach to Anticoagulation Therapy in Patients with Combined Atrial Fibrillation and Coronary Artery Stents: A Review of the Literature.","authors":"Ben Borokhovsky, Perry J Weinstock","doi":"10.15420/ecr.2023.18.PO4","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO4","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/91/ecr-18-e21.PMC10316348.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronary Spasm: Ethnic and Sex Differences. 冠状动脉痉挛:种族和性别差异。
IF 3 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.13
Peter Ong, Astrid Hubert, Maike Schwidder, John F Beltrame

Coronary spasm (CS), which may occur at the epicardial (focal or diffuse spasm) and/or microvascular (microvascular spasm) level, is a well-established cause of myocardial ischaemia, in particular in patients with anginal chest pain despite unobstructed coronary arteries. The diagnosis of CS can be confirmed during coronary angiography by an additional provocation test with vasoactive substances such as acetylcholine. Due to partially inconsistent data from large clinical studies, especially between Asian and white CS patients, ethnic differences concerning the prevalence and angiographic patterns of CS seem to exist. Furthermore, several studies in patients with coronary vasomotor disorders pointed towards differences among male and female CS patients. This article gives an overview of ethnic- and sex-related differences in patients with CS.

冠状动脉痉挛(CS)可能发生在心外膜(局灶性或弥漫性痉挛)和/或微血管(微血管痉挛)水平,是心肌缺血的一个公认原因,特别是在冠状动脉通畅的心绞痛胸痛患者中。CS的诊断可以在冠状动脉造影时通过血管活性物质(如乙酰胆碱)的额外激发试验来证实。由于大型临床研究的部分数据不一致,特别是在亚洲和白人CS患者之间,CS的患病率和血管造影模式似乎存在种族差异。此外,一些对冠状动脉血管舒缩性疾病患者的研究表明,男性和女性CS患者存在差异。本文概述了CS患者的种族和性别相关差异。
{"title":"Coronary Spasm: Ethnic and Sex Differences.","authors":"Peter Ong,&nbsp;Astrid Hubert,&nbsp;Maike Schwidder,&nbsp;John F Beltrame","doi":"10.15420/ecr.2023.13","DOIUrl":"https://doi.org/10.15420/ecr.2023.13","url":null,"abstract":"<p><p>Coronary spasm (CS), which may occur at the epicardial (focal or diffuse spasm) and/or microvascular (microvascular spasm) level, is a well-established cause of myocardial ischaemia, in particular in patients with anginal chest pain despite unobstructed coronary arteries. The diagnosis of CS can be confirmed during coronary angiography by an additional provocation test with vasoactive substances such as acetylcholine. Due to partially inconsistent data from large clinical studies, especially between Asian and white CS patients, ethnic differences concerning the prevalence and angiographic patterns of CS seem to exist. Furthermore, several studies in patients with coronary vasomotor disorders pointed towards differences among male and female CS patients. This article gives an overview of ethnic- and sex-related differences in patients with CS.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/81/ecr-18-e43.PMC10345948.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
How to Improve Clinical Outcomes and Reduce Cardiovascular Risk in Older People with Cardiovascular Disease: Bridging Evidence Gaps. 如何改善老年心血管疾病患者的临床结果并降低心血管风险:弥合证据差距
IF 3 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.15420/ecr.2022.59
Mauricio Wajngarten

The geriatric population is greatly impacted by cardiovascular disease. Thus, it becomes essential to 'geriatricise' the cardiologist through the dissemination of geriatric cardiology. In the early days of geriatric cardiology, it was discussed whether it was simply cardiology 'well done'. Today, 40 years later, it seems clear that this is indeed the case. Patients with cardiovascular disease usually have several chronic conditions. Clinical practice guidelines often address a single condition and do not provide sufficient guidance for patients with multimorbidity. There are several evidence gaps regarding these patients. Physicians and members ofthe care team need a multidimensional understanding ofthe patient to better promote the optimisation of care. It is important to understand that ageing is inevitable, heterogeneous and increases vulnerability. Caregivers must know how to assess elderly patients in a multidomain practical way and how to recognise the factors that may have implications on treatment.

老年人口受心血管疾病的影响很大。因此,通过老年心脏病学的传播使心脏病专家“老年化”变得至关重要。在老年心脏病学的早期,人们讨论过这是否仅仅是心脏病学“做得好”。40年后的今天,情况似乎确实如此。心血管疾病患者通常有几种慢性疾病。临床实践指南通常针对单一病症,不能为多病患者提供足够的指导。关于这些患者,存在一些证据缺口。医生和护理团队成员需要对患者有一个多维度的了解,以更好地促进护理的优化。重要的是要明白,老龄化是不可避免的、异质性的,而且会增加脆弱性。护理人员必须知道如何以多领域实用的方式评估老年患者,以及如何识别可能对治疗产生影响的因素。
{"title":"How to Improve Clinical Outcomes and Reduce Cardiovascular Risk in Older People with Cardiovascular Disease: Bridging Evidence Gaps.","authors":"Mauricio Wajngarten","doi":"10.15420/ecr.2022.59","DOIUrl":"https://doi.org/10.15420/ecr.2022.59","url":null,"abstract":"<p><p>The geriatric population is greatly impacted by cardiovascular disease. Thus, it becomes essential to 'geriatricise' the cardiologist through the dissemination of geriatric cardiology. In the early days of geriatric cardiology, it was discussed whether it was simply cardiology 'well done'. Today, 40 years later, it seems clear that this is indeed the case. Patients with cardiovascular disease usually have several chronic conditions. Clinical practice guidelines often address a single condition and do not provide sufficient guidance for patients with multimorbidity. There are several evidence gaps regarding these patients. Physicians and members ofthe care team need a multidimensional understanding ofthe patient to better promote the optimisation of care. It is important to understand that ageing is inevitable, heterogeneous and increases vulnerability. Caregivers must know how to assess elderly patients in a multidomain practical way and how to recognise the factors that may have implications on treatment.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/2d/ecr-18-e17.PMC10316345.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Presentation Award Winner: Appropriateness of Antiplatelet Pretreatment in Non-ST-segment Elevation Acute Coronary Syndrome: Differences Between Unstable Angina and Acute Myocardial Infarction. 口头报告奖得主:非st段抬高急性冠状动脉综合征抗血小板预处理的适宜性:不稳定型心绞痛与急性心肌梗死的差异。
IF 3 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO3
G Torres-Ruiz, P Rojas-Flores, N Mallofré Vila, E Bosch-Peligero, A Martínez-Rubio
{"title":"Oral Presentation Award Winner: Appropriateness of Antiplatelet Pretreatment in Non-ST-segment Elevation Acute Coronary Syndrome: Differences Between Unstable Angina and Acute Myocardial Infarction.","authors":"G Torres-Ruiz,&nbsp;P Rojas-Flores,&nbsp;N Mallofré Vila,&nbsp;E Bosch-Peligero,&nbsp;A Martínez-Rubio","doi":"10.15420/ecr.2023.18.PO3","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO3","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ab/99/ecr-18-e20.PMC10316336.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Cardiology Review
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1